Geisinger researchers will work with collaborators at the nonprofit FH Foundation to develop new methods for the identification and cascade testing of FH.
A team led by researchers at the NHLBI are testing the efficacy of measuring ddcfDNA in blood as a biomarker of chronic rejection for lung transplants.
Nucleosome organization appears to follow two principles, according to the researchers' analyses of three different cell types.
Participants in the pilot will begin developing the capabilities required for the planned data commons, including making data transparent and interoperable.
The funding will support research projects using data from the Trans Omics for Precision Medicine program to uncover disease pathology.
Eleven new studies from the NHLBI NextGen Consortium show different uses for iPSCs to study polygenetic diseases across various systems in the human body.
The partners are developing an assay to detect minimal residual disease in leukemia patients, for use with Sellas' investigational AML drug.
Funded projects will support the agency's Trans Omics for Precision Medicine program, which is focused on heart, lung, blood, and sleep disorders.
The CCHMC will act as the coordinating center for members of the NHLBI's Cardiovascular Development Consortium and Pediatric Cardiac Genomics Consortium.
The center has already sequenced and analyzed 1,500 human genomes for the TOPMed program and will expand this effort with the new funding.
Gene editing could be an issue competitive sports need to address soon, four researchers from Arizona State University write at Slate.
A genetic alteration appears to increase heart failure risk among people of African descent, according to the Washington Post.
In his look back at the past decade, BuzzFeed News' Peter Aldhous writes that direct-to-consumer genetic testing has led to "Facebook for genes."
In Nature this week: genetic "clock" that can predict the lifespans of vertebrates, new assembler called wtdbg2, and more.